Medipost Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
334
- Stock Symbol
-
078160
- Investments
-
2
- Share Price
-
$5.77
- (As of Friday Closing)
Medipost General Information
Description
Medipost Co Ltd is a Korea-based stem cell biotechnology company. The company is engaged in developing products to meet unmet medical needs. The company operates its business through four distinct segments: Stem Cell Therapeutics, Cord Blood Bank, Cosmetics, and Health Supplements. The Cord Blood Bank Division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapeutics division manufactures allogeneic stem cell drug products. The Health Supplements division offers vitamins and nutritional supplements. The Cosmetics division is involved in the sales and marketing of natural cosmetics.
Contact Information
Website
www.medi-post.co.krCorporate Office
- 21 Daewangpangyo-ro 644
- Bundang-gu
- Seongnam, Gyeonggi-do 137-874
- South Korea
Corporate Office
- 21 Daewangpangyo-ro 644
- Bundang-gu
- Seongnam, Gyeonggi-do 137-874
- South Korea
Medipost Stock Performance
As of 20-Nov-2026, Medipost’s stock price is $5.77. Its current market cap is $226M with 39.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.77 | $6.03 | $5.02 - $19.74 | $226M | 39.1M | 50.1K | -$0.46 |
Medipost Financials Summary
As of 30-Jun-2026, Medipost has a trailing 12-month revenue of $51.6M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 186,068 | 477,240 | 200,064 | 151,392 |
| Revenue | 51,572 | 51,757 | 51,785 | 52,501 |
| EBITDA | (12,042) | (57,252) | (43,835) | 10,815 |
| Net Income | (15,900) | (60,007) | (45,825) | 4,467 |
| Total Assets | 362,199 | 299,686 | 281,260 | 348,723 |
| Total Debt | 103,724 | 28,055 | 7,571 | 9,035 |
Medipost Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Medipost Patents
Medipost Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024543218-A | Composition for preventing or treating lung disease comprising cd47-overexpressing mesenchymal stem cells | Pending | 01-Dec-2021 | ||
| AU-2022403380-A1 | Composition for preventing or treating lung diseases containing cd47-overexpressing mesenchymal stem cells | Pending | 01-Dec-2021 | ||
| CA-3239499-A1 | Composition for preventing or treating lung diseases containing cd47-overexpressing mesenchymal stem cells | Pending | 01-Dec-2021 | ||
| EP-4442263-A1 | Composition for preventing or treating lung diseases containing cd47-overexpressing mesenchymal stem cells | Pending | 01-Dec-2021 | ||
| EP-4442263-A4 | Composition for preventing or treating lung diseases containing cd47-overexpressing mesenchymal stem cells | Pending | 01-Dec-2021 | A61K35/28 |
Medipost Signals
Medipost Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Medipost Investments & Acquisitions (2)
Medipost’s most recent deal was a Secondary Transaction - Private with OmniaBio for . The deal was made on 31-May-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| OmniaBio | 31-May-2022 | Secondary Transaction - Private | Other Pharmaceuticals and Biotechnology | ||
| Immunique | 01-Apr-2021 | Merger/Acquisition | Drug Discovery |
Medipost ESG
Risk Overview
Risk Rating
Updated October, 31, 2024
28.19 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,201
Rank
Percentile
Healthcare
Industry
of 592
Rank
Percentile
Medical Services
Subindustry
of 104
Rank
Percentile
Medipost Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Immunique | Seongnam, South Korea | 2021 |
Medipost FAQs
-
When was Medipost founded?
Medipost was founded in 2000.
-
Where is Medipost headquartered?
Medipost is headquartered in Seongnam, South Korea.
-
What is the size of Medipost?
Medipost has 334 total employees.
-
What industry is Medipost in?
Medipost’s primary industry is Biotechnology.
-
Is Medipost a private or public company?
Medipost is a Public company.
-
What is Medipost’s stock symbol?
The ticker symbol for Medipost is 078160.
-
What is the current stock price of Medipost?
As of 20-Nov-2026 the stock price of Medipost is $5.77.
-
What is the current market cap of Medipost?
The current market capitalization of Medipost is $226M.
-
What is Medipost’s current revenue?
The trailing twelve month revenue for Medipost is $51.6M.
-
What is Medipost’s annual earnings per share (EPS)?
Medipost’s EPS for 12 months was -$0.46.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process